[外周动脉疾病:2024 年更新]。

Dilara Arslan, Roxani Psychogyiou, Lukas Briner, Jacques Donzé
{"title":"[外周动脉疾病:2024 年更新]。","authors":"Dilara Arslan, Roxani Psychogyiou, Lukas Briner, Jacques Donzé","doi":"10.53738/REVMED.2024.20.897.2249","DOIUrl":null,"url":null,"abstract":"<p><p>Peripheral arterial disease (PAD) is a major public health issue, with a growing prevalence due to the aging population and the rise in risk factors such as diabetes, hypertension, and dyslipidemia. Managing PAD involves a multidisciplinary approach, with the primary care physician playing a crucial role in early screening. This article compiles the latest data from 2024 and current practices for the management of this disease. In simplified terms, all symptomatic patients should receive single antiplatelet therapy, and all post-revascularization patients should be on at least DAPT (Dual Antiplatelet Therapy) orDPI (Dual Pathway Inhibition), as recommended by the European Society for Vascular Surgery 2024 guidelines.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"20 897","pages":"2249-2252"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Peripheral arterial disease: 2024 update].\",\"authors\":\"Dilara Arslan, Roxani Psychogyiou, Lukas Briner, Jacques Donzé\",\"doi\":\"10.53738/REVMED.2024.20.897.2249\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Peripheral arterial disease (PAD) is a major public health issue, with a growing prevalence due to the aging population and the rise in risk factors such as diabetes, hypertension, and dyslipidemia. Managing PAD involves a multidisciplinary approach, with the primary care physician playing a crucial role in early screening. This article compiles the latest data from 2024 and current practices for the management of this disease. In simplified terms, all symptomatic patients should receive single antiplatelet therapy, and all post-revascularization patients should be on at least DAPT (Dual Antiplatelet Therapy) orDPI (Dual Pathway Inhibition), as recommended by the European Society for Vascular Surgery 2024 guidelines.</p>\",\"PeriodicalId\":21286,\"journal\":{\"name\":\"Revue medicale suisse\",\"volume\":\"20 897\",\"pages\":\"2249-2252\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue medicale suisse\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53738/REVMED.2024.20.897.2249\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale suisse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53738/REVMED.2024.20.897.2249","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

外周动脉疾病(PAD)是一个重大的公共卫生问题,由于人口老龄化以及糖尿病、高血压和血脂异常等危险因素的增加,其发病率也在不断上升。治疗 PAD 需要采用多学科方法,而初级保健医生在早期筛查中发挥着至关重要的作用。本文汇集了 2024 年的最新数据以及目前治疗该疾病的方法。简而言之,根据欧洲血管外科学会2024年指南的建议,所有有症状的患者都应接受单一抗血小板治疗,所有血管重建后的患者都应至少接受DAPT(双重抗血小板治疗)或DPI(双重通路抑制)治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Peripheral arterial disease: 2024 update].

Peripheral arterial disease (PAD) is a major public health issue, with a growing prevalence due to the aging population and the rise in risk factors such as diabetes, hypertension, and dyslipidemia. Managing PAD involves a multidisciplinary approach, with the primary care physician playing a crucial role in early screening. This article compiles the latest data from 2024 and current practices for the management of this disease. In simplified terms, all symptomatic patients should receive single antiplatelet therapy, and all post-revascularization patients should be on at least DAPT (Dual Antiplatelet Therapy) orDPI (Dual Pathway Inhibition), as recommended by the European Society for Vascular Surgery 2024 guidelines.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revue medicale suisse
Revue medicale suisse Medicine-Medicine (all)
CiteScore
0.60
自引率
0.00%
发文量
1210
期刊介绍: Destinée aux professionnels de santé, la plateforme revmed.ch regroupe la version électronique de la Revue Médicale Suisse et les applications de formation et d"aide à la prise de décision eRMS. La eRMS est le fruit d’une large collaboration entre institutions et praticiens de Suisse romande.
期刊最新文献
[Nephrology : what's new in 2024 (II)]. [Neurorehabilitation in Parkinson's disease : focus on physical therapy]. [Cardiology. Rhythmology, hypertension, dyslipidemia and aortic diseases]. [Endocrinology : what's new in 2024]. [Oncology. Antibody-drug conjugates : a challenging innovation].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1